Author Archives: Alessio Aghemo, Massimo Colombo

Glecaprevir/Pibrentasvir: The Final Piece in the HCV Treatment Puzzle?

Posted on February 1, 2018 by Alessio Aghemo, Massimo Colombo
Posted in News | Comments Off on Glecaprevir/Pibrentasvir: The Final Piece in the HCV Treatment Puzzle?

Response-Guided Duration of Directly Acting Antiviral Therapy for Chronic Hepatitis C: Back to the Future?

Posted on February 27, 2017 by Alessio Aghemo, Massimo Colombo

Lau G, Benhamou Y, Chen G, et al. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol 2016;1:97–104. Continue reading →

Posted in News | Comments Off on Response-Guided Duration of Directly Acting Antiviral Therapy for Chronic Hepatitis C: Back to the Future?

Will the Benefits of Treatment for Chronic Hepatitis C Be Retained in the Interferon-free Era?

Posted on June 27, 2015 by Alessio Aghemo, Massimo Colombo

Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 2015;64:495–504. Continue reading →

Posted in News | Comments Off on Will the Benefits of Treatment for Chronic Hepatitis C Be Retained in the Interferon-free Era?